Plas-Free
Grant-FundedCORDISBlood filtration systems using single-use ClearPlasma device
Deep Tech · Digital Health
Around 40% of deaths worldwide are due to bleeding, which establishes haemorrhage as the most common cause of preventable death. Early intervention is generally sought by transfusing red blood cells, plasma, and platelets at a ratio of 1:1:1; however, this can lead to increased bleeding
and death. PlasFree is tackling this unmet demand of novel therapeutic approaches for haemorrhage by developing ClearPlasma™, an innovative filtration system that extracts plasminogen from plasma, leading to an efficient treatment for massive bleeding. ClearPlasma™ also allows to reduce up
to 45% of the number of plasma units required during transfusion. PlasFree will be part of a booming global blood transfusion market valued at €6.34 billion. With the EIC support, PlasFree aims to deliver substantial global impact, for patients and healthcare systems, by accelerating the
development of ClearPlasma™ as well as scaling-up and conducting clinical validation to prove the device’s safety and efficacy.
EU Grants€1.3M
Team
ZD
Zeev Dvashi
Founder
All-time revenue—
MRRPrivate••••••
FounderZeev Dvashi
Founded—
🇮🇱Israel
RevenuePrivate
Revenue data is privateThis company has chosen not to share revenue metrics
Startup insights
Business detailsB2B
Deep TechDigital Health
Tags:Deep TechDigital Health
Company Info
Plas-Free Info
Funding
EU Grants€1.3M
